Brief: Catalyst Biosciences Regains Rights To CB 2782-Peg For Treatment Of Dry AMD

Gyre Therapeutics

15/03/2022 21:25

March 15 (Reuters) - Catalyst Biosciences Inc  CBIO.O :
    * CATALYST BIOSCIENCES REGAINS RIGHTS TO CB 2782-PEG FOR THE
TREATMENT OF DRY AMD EXPANDS CBIO’S COMPLEMENT PORTFOLIO IN
OPHTHALMOLOGY
    * CATALYST BIOSCIENCES REGAINS RIGHTS TO CB 2782-PEG FOR THE
TREATMENT OF DRY AMD EXPANDS CBIO’S COMPLEMENT PORTFOLIO IN
OPHTHALMOLOGY
    * CATALYST BIOSCIENCES - BIOGEN HAS RETURNED RIGHTS FOR
FURTHER
DEVELOPMENT ON CB 2782-PEG & HAS ENDED COLLABORATION ON OTHER
POTENTIAL AMD TREATMENTS

Source text for Eikon:  ID:nGNX8kR9Rd 
Further company coverage:  CBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))